ES2830446T3 - Derivado de azetidina, método de preparación del mismo y uso del mismo - Google Patents

Derivado de azetidina, método de preparación del mismo y uso del mismo Download PDF

Info

Publication number
ES2830446T3
ES2830446T3 ES16872413T ES16872413T ES2830446T3 ES 2830446 T3 ES2830446 T3 ES 2830446T3 ES 16872413 T ES16872413 T ES 16872413T ES 16872413 T ES16872413 T ES 16872413T ES 2830446 T3 ES2830446 T3 ES 2830446T3
Authority
ES
Spain
Prior art keywords
reaction
compound
mmol
pyrrolo
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16872413T
Other languages
English (en)
Spanish (es)
Inventor
Yinong Xie
Zejin You
Zhiwen Deng
Jun Zhu
Ao Wang
Yan Feng
Dong Long
Hong Zeng
Hongmei Song
Qijun Ye
Wei Qi
Donghai Su
Lichun Wang
Jingyi Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Original Assignee
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Kelun Biotech Biopharmaceutical Co Ltd filed Critical Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2830446T3 publication Critical patent/ES2830446T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES16872413T 2015-12-11 2016-12-08 Derivado de azetidina, método de preparación del mismo y uso del mismo Active ES2830446T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510924946 2015-12-11
PCT/CN2016/109036 WO2017097224A1 (zh) 2015-12-11 2016-12-08 氮杂环丁烷衍生物、其制备方法及用途

Publications (1)

Publication Number Publication Date
ES2830446T3 true ES2830446T3 (es) 2021-06-03

Family

ID=59012693

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16872413T Active ES2830446T3 (es) 2015-12-11 2016-12-08 Derivado de azetidina, método de preparación del mismo y uso del mismo

Country Status (8)

Country Link
US (3) US10159662B2 (OSRAM)
EP (1) EP3360878B9 (OSRAM)
JP (1) JP6860267B2 (OSRAM)
CN (1) CN108137603B (OSRAM)
DK (1) DK3360878T3 (OSRAM)
ES (1) ES2830446T3 (OSRAM)
HK (1) HK1250707B (OSRAM)
WO (1) WO2017097224A1 (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108137603B (zh) * 2015-12-11 2019-10-18 四川科伦博泰生物医药股份有限公司 氮杂环丁烷衍生物、其制备方法及用途
AU2018209579B2 (en) * 2017-01-23 2020-12-24 Shanghai Longwood Biopharmaceuticals Co., Ltd. JAK kinase inhibitor and preparation method and use thereof
ES2937823T3 (es) * 2017-06-07 2023-03-31 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Forma sólida del derivado de azetidina y método de preparación del mismo y uso del mismo
BR112020008850A2 (pt) 2017-11-03 2020-10-20 Aclaris Therapeutics, Inc. composto, composição farmacêutica e método para tratar uma doença mediada por jak1 e jak3
US10800775B2 (en) 2017-11-03 2020-10-13 Aclaris Therapeutics, Inc. Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same
CN109867675B (zh) * 2017-12-01 2021-01-19 北京普祺医药科技有限公司 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途
TW201940483A (zh) * 2018-03-12 2019-10-16 美商艾伯維有限公司 酪胺酸激酶２介導的傳訊之抑制劑
CN119080779A (zh) 2018-08-10 2024-12-06 阿克拉瑞斯治疗股份有限公司 吡咯并嘧啶itk抑制剂
CN111320633B (zh) * 2018-12-14 2022-09-27 中国医药研究开发中心有限公司 吡咯/咪唑并六元杂芳环类化合物及其制备方法和医药用途
CN111518096B (zh) * 2019-02-02 2022-02-11 江苏威凯尔医药科技有限公司 两面神激酶jak家族抑制剂及其制备和应用
CN113508114B (zh) * 2019-02-27 2024-03-26 四川科伦博泰生物医药股份有限公司 以氮杂环丁烷衍生物为活性成分的口服药物组合物、其制备方法及用途
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
JP7256291B2 (ja) 2019-04-12 2023-04-11 プライムジーン（ベイジン）カンパニー リミテッド ピラゾロピラジン誘導の化合物、医薬組成物およびその使用
AU2020265828A1 (en) 2019-05-02 2021-09-09 Aclaris Therapeutics, Inc. Substituted pyrrolopyridines as JAK inhibitors
CN110028432A (zh) * 2019-05-22 2019-07-19 南京合巨药业有限公司 一种（3-氨基-氮杂环丁烷-1-基）-环丙基-甲酮的制备方法
WO2020240586A1 (en) * 2019-05-28 2020-12-03 Mankind Pharma Ltd. Novel compounds for inhibition of janus kinase 1
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JP2025509642A (ja) 2022-03-18 2025-04-11 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド アゼチジン誘導体の使用および治療方法
WO2023226822A1 (zh) * 2022-05-26 2023-11-30 四川科伦博泰生物医药股份有限公司 氮杂环丁烷衍生物治疗病毒感染的方法及用途
CN115974864B (zh) * 2022-12-29 2025-09-16 苏州汉德创宏生化科技有限公司 一种2-(3-氮杂环丁基)噻唑盐的合成方法
WO2024148184A1 (en) * 2023-01-04 2024-07-11 Aerie Pharmaceuticals, Inc. Compounds and processes for the preparation of jak inhibitors
EP4653439A1 (en) * 2023-01-18 2025-11-26 Prime Gene Therapeutics Co., Ltd. Azacycloalkane compound and pharmaceutical composition, and use thereof
CN116444529B (zh) * 2023-06-16 2023-12-05 药康众拓(江苏)医药科技有限公司 一种氘代氮杂环丁烷类jak抑制剂及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2435769C2 (ru) 2005-05-20 2011-12-10 Вертекс Фармасьютикалз Инкорпорейтед Пирролопиридины, полезные в качестве ингибиторов протеинкиназы
MX2010010012A (es) * 2008-03-11 2010-10-20 Incyte Corp Derivados de azetidina y ciclobutano como inhibidores de jak.
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
PH12015502575A1 (en) * 2010-03-10 2017-04-24 Incyte Corp Piperidin-4-yl azetidine derivatives as jak1 inhibitors
US8691807B2 (en) * 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
WO2013173506A2 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
NZ763326A (en) 2014-04-08 2023-04-28 Incyte Holdings Corp Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
CN117736209A (zh) 2015-02-27 2024-03-22 因赛特控股公司 Pi3k抑制剂的盐及其制备方法
RU2601410C1 (ru) * 2015-11-13 2016-11-10 ЗАО "Р-Фарм" {3-[(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АЗОЛИЛ]АЗЕТИДИН-3-ИЛ}АЦЕТОНИТРИЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС КИНАЗ
CN108137603B (zh) * 2015-12-11 2019-10-18 四川科伦博泰生物医药股份有限公司 氮杂环丁烷衍生物、其制备方法及用途

Also Published As

Publication number Publication date
CN108137603A (zh) 2018-06-08
HK1251551A1 (en) 2019-02-01
HK1250707B (zh) 2020-07-03
US20200147062A1 (en) 2020-05-14
EP3360878B9 (en) 2021-05-05
EP3360878B1 (en) 2020-09-16
US20190060291A1 (en) 2019-02-28
CN108137603B (zh) 2019-10-18
US11045455B2 (en) 2021-06-29
US20180289680A1 (en) 2018-10-11
DK3360878T3 (da) 2020-11-09
JP2018536634A (ja) 2018-12-13
EP3360878A1 (en) 2018-08-15
JP6860267B2 (ja) 2021-04-14
WO2017097224A1 (zh) 2017-06-15
EP3360878A4 (en) 2019-03-06
US10159662B2 (en) 2018-12-25

Similar Documents

Publication Publication Date Title
ES2830446T3 (es) Derivado de azetidina, método de preparación del mismo y uso del mismo
ES2967866T3 (es) Compuestos de pirrolotriazina como inhibidores de TAM
JP2022110135A (ja) Ｓｙｋ阻害剤としての縮合複素芳香族ピロリジノン
ES2551592T3 (es) Pirazolo[1,5-a]piridinas como inhibidores de TRK
ES2908412T3 (es) Derivados de piperidin-4-IL azetidina como inhibidores de JAK1
JP6629847B2 (ja) 縮合五員環イミダゾール誘導体
ES2377358T3 (es) Compuestos farmacéuticos
ES2487542T3 (es) Derivados de N-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de cinasas Janus
ES2654288T3 (es) Moduladores de P2X7
US9351974B2 (en) Substituted pteridinones for the treatment of cancer
CN106459057B (zh) 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物
JP2023505258A (ja) Ｆｇｆｒ阻害剤としての三環式複素環
ES2770693T3 (es) Derivados de imidazopiridazina como inhibidores de caseína quinasa 1 delta/épsilon
CA2953798A1 (en) Aminopyridazinone compounds as protein kinase inhibitors
EP3524603A1 (en) Fgfr4 inhibitor, preparation method therefor and pharmaceutical use thereof
JP2011526931A (ja) Ｃｄｋモジュレーター
TW201326173A (zh) ５，７－經取代之－咪唑并［１，２－ｃ］嘧啶
RU2515541C2 (ru) N-7 замещенные пурины и пиразолопиримидины, их композиции и способы применения
HUE032720T2 (en) Pyridinyl and fused pyridinyl triazolone derivatives
CN102596962A (zh) Jak抑制剂
CA2998705A1 (en) 1-phenylpyrrolidin-2-one derivatives as perk inhibitors
TW201639845A (zh) 新的雜芳基和雜環化合物、其組成物及方法
JP2023537055A (ja) Ａｔｒ阻害剤およびその使用
ES2645508T3 (es) Inhibidores de cinasa macrocíclica
HK1251551B (en) Azetidine derivative, preparation method therefor, and use thereof